Edwards Lifesciences (EW) surged nearly 7% in after-hours trade on July 23 after second-quarter revenue of $1.74 billion and adjusted earnings of $0.78 per share both cleared Wall Street forecasts by a meaningful margin, driven by accelerating adoption of its flagship heart-valve...